NASDAQ:ISO IsoPlexis (ISO) Stock Price, News & Analysis → The new financial threat that could wipe out millions… (From InvestorPlace) (Ad) Free ISO Stock Alerts Notice: This company has been marked as potentially delisted and may not be actively trading. Add Compare Share Share Today's Range$0.76▼$0.7650-Day Range$0.74▼$1.1352-Week Range$0.60▼$5.10VolumeN/AAverage Volume68,375 shsMarket Capitalization$30.28 millionP/E RatioN/ADividend YieldN/APrice TargetN/A Stock AnalysisStock Analysis Get IsoPlexis alerts: Email Address Ad Colonial MetalsConflict In Israel Sends Gold Soaring ???? Here’s How To Get Your ShareThe latest flare-up between Israel and Palestinian militants has sent gold prices surging. Why? Because savvy investors know the endgame of the elites at play… Geopolitical crises breed uncertainty — and gold thrives on uncertainty. See why the elites are pouring billions into gold. About IsoPlexis Stock (NASDAQ:ISO)IsoPlexis Corporation, a life sciences company, provides solutions for the development of curative medicines and personalized therapeutics in the United States, Canada, the United Kingdom, Belgium, France, the Czech Republic, Spain, Germany, Sweden, Italy, Israel, Switzerland, China and Taiwan, Singapore, Japan, Australia, and Korea. The company offers single cell proteomics platform, including instruments, chip consumables, and software that provides an end-to-end solution to view of protein function at an individual cellular level. It provides IsoLight and IsoSpark instruments; IsoCode chips that offer multiplexed chip solutions for single cell functional proteomics; CodePlex chips that provide multiplexed solutions for ultra-low volume bulk samples; and IsoSpeak software that offers dimensional data and automates analysis with an intuitive push button user interface to deliver same day single cell and bulk proteome visualizations, as well as research support and services, and post-warranty services. The company was incorporated in 2013 and is based in Branford, Connecticut.Read More Ad Colonial MetalsConflict In Israel Sends Gold Soaring ???? Here’s How To Get Your ShareThe latest flare-up between Israel and Palestinian militants has sent gold prices surging. Why? Because savvy investors know the endgame of the elites at play… Geopolitical crises breed uncertainty — and gold thrives on uncertainty. See why the elites are pouring billions into gold. ISO Stock News HeadlinesMarch 5, 2024 | uk.finance.yahoo.comDiagnostic Industry Revelations: Comprehensive Analysis of Global Distribution Deals from 2016 to 2024 UnveiledAugust 18, 2023 | msn.comBruker to buy cell biology company PhenomeX for $108mMay 8, 2024 | InvestorPlace (Ad)The new financial threat that could wipe out millions…During the Internet boom, companies like Pets.com were supposed to be promising investments riding the wave of a new tech boom. But then they were gone within a blink of an eye. One of the most successful investors in history just stepped forward to say the same thing is about to happen to AI stocks.August 17, 2023 | msn.comBruker Enters Functional Single-Cell Biology Research Solutions With PhenomeX AcquisitionAugust 17, 2023 | msn.comPhenomeX stock rallies by 137% after buyout offer from BrukerAugust 17, 2023 | finance.yahoo.comBruker Corporation and PhenomeX Inc. Announce Definitive Agreement for Bruker to Acquire PhenomeX in All-Cash TransactionAugust 14, 2023 | markets.businessinsider.comPhenomeX Reports Second Quarter 2023 Financial Results and Provides Business UpdateAugust 11, 2023 | thestreet.comIsoPlexis CorporationMay 8, 2024 | InvestorPlace (Ad)The new financial threat that could wipe out millions…During the Internet boom, companies like Pets.com were supposed to be promising investments riding the wave of a new tech boom. But then they were gone within a blink of an eye. One of the most successful investors in history just stepped forward to say the same thing is about to happen to AI stocks.May 16, 2023 | marketwatch.com10-Q: PHENOMEX INC.May 12, 2023 | finanznachrichten.dePhenomeX Reports First Quarter 2023 Financial ResultsMay 5, 2023 | marketwatch.comSingle Cell Proteomics System Market Insights, Forecast to 2029 Market Size 2023-2031 Industrial Regions by Absolute Reports | with [90 Pages]May 3, 2023 | marketwatch.comSingle Cell Proteomics Analysis System Market Insights, Forecast to 2029 Market Size and volume sale report 2023April 14, 2023 | marketwatch.comTabula Rasa HealthCare Removes Interim Tag, Names Brian Adams CEOMarch 21, 2023 | finance.yahoo.comPhenomeX Strengthens Commercial Leadership TeamFebruary 18, 2023 | finance.yahoo.comIsoPlexis Corporation (ISO) Stock Historical Prices & Data - Yahoo FinanceFebruary 9, 2023 | finance.yahoo.comIsoPlexis Corporation's (NASDAQ:ISO) recent US$6.3m market cap decline means a loss of US$65k for insiders who bought this yearFebruary 4, 2023 | benzinga.comSHAREHOLDER ALERT: Weiss Law Investigates IsoPlexis CorporationJanuary 15, 2023 | finanznachrichten.deIsoPlexis Corporation: Berkeley Lights to Acquire IsoPlexis, Creating a Premier Functional Cell Biology CompanyJanuary 12, 2023 | benzinga.comIsoPlexis Granted U.S. Patent Titled 'METHODS OF USING NUCLEOTIDE ANALOGUES'January 12, 2023 | msn.comIsoPlexis expects FY22 revenue to be below consensusJanuary 12, 2023 | finance.yahoo.comIsoPlexis Reports Preliminary Full Year 2022 RevenueJanuary 10, 2023 | msn.comBerkeley Lights' Preliminary 2022 Results Deficient, Analysts Say All Eyes On IsoPlexis ExecutionJanuary 5, 2023 | msn.comMorgan Stanley Maintains Equal-Weight Rating for IsoPlexis: Here's What You Need To KnowDecember 23, 2022 | barrons.comThinking about buying stock in Mullen Automotive, Cleveland-Cliffs, CarMax, IsoPlexis, or Teva Pharmaceutical?December 23, 2022 | markets.businessinsider.comAnalysts Conflicted on These Technology Names: Workday (WDAY) and IsoPlexis (ISO)December 23, 2022 | benzinga.comSHAREHOLDER ALERT: Rigrodsky Law, P.A. Is Investigating IsoPlexis Corporation BuyoutSee More Headlines Receive ISO Stock News and Ratings via Email Sign-up to receive the latest news and ratings for IsoPlexis and its competitors with MarketBeat's FREE daily newsletter. Email Address Company Calendar Last Earnings11/10/2021Today5/08/2024Fiscal Year End12/31/2024Get Stock AlertsIndustry, Sector and Symbol Stock ExchangeNASDAQ SectorMedical Industry Analytical instruments Sub-IndustryN/A Current SymbolNASDAQ:ISO CUSIPN/A CIK1615055 Webisoplexis.com Phone203-208-4111FaxN/AEmployees459Year FoundedN/AProfitability EPS (Most Recent Fiscal Year)($2.70) Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/ANet Income$-106,000,000.00 Net Margins-632.41% Pretax Margin-632.40% Return on Equity-127.86% Return on Assets-71.41% Debt Debt-to-Equity Ratio1.12 Current Ratio4.06 Quick Ratio2.50 Sales & Book Value Annual Sales$16.76 million Price / Sales1.81 Cash FlowN/A Price / Cash FlowN/A Book Value$1.04 per share Price / Book0.73Miscellaneous Outstanding Shares39,760,000Free Float37,218,000Market Cap$30.28 million OptionableNot Optionable Beta1.32 Investing Strategies To Help Grow Your Retirement IncomeNeed to stretch out your 401K or Roth IRA plan? Use these time-tested investing strategies to grow the monthly retirement income that your stock portfolio generates.Get This Free Report Key ExecutivesMr. Sean Mackay (Age 40)Co-Founder, CEO, Pres & Director Comp: $635.55kMr. John R. Strahley CPA (Age 55)Chief Financial Officer Comp: $444.11kMr. Rong FanCo-Founder & Chairman of Scientific Advisory BoardMr. Jon ChenVP of Scientific Alliance Technology & Co-FounderMr. Anthony CatalanoSr. VP of OperationsMr. Rajesh T. KhakharVP of Fin. & Principal Accounting OfficerMs. Jing Zhou M.D. (Age 52)Ph.D., Chief Scientific Officer Mr. Richard W. Rew II (Age 54)Sr. VP, Gen. Counsel & Sec. Ms. Verna SiuSr. VP of Sales OperationsMs. Carrie CarterSr. VP of People OperationsMore ExecutivesKey CompetitorsSingular Genomics SystemsNASDAQ:OMICRapid Micro BiosystemsNASDAQ:RPIDCue HealthNASDAQ:HLTHAccelerate DiagnosticsNASDAQ:AXDXTalis BiomedicalNASDAQ:TLISView All Competitors ISO Stock Analysis - Frequently Asked Questions How were IsoPlexis' earnings last quarter? IsoPlexis Co. (NASDAQ:ISO) posted its quarterly earnings results on Wednesday, November, 10th. The company reported ($10.66) EPS for the quarter, missing the consensus estimate of ($0.79) by $9.87. The company earned $4.19 million during the quarter, compared to analysts' expectations of $3.79 million. IsoPlexis had a negative trailing twelve-month return on equity of 127.86% and a negative net margin of 632.41%. When did IsoPlexis IPO? IsoPlexis (ISO) raised $125 million in an IPO on Friday, October 8th 2021. The company issued 8,333,000 shares at a price of $14.00-$16.00 per share. This page (NASDAQ:ISO) was last updated on 5/8/2024 by MarketBeat.com Staff From Our PartnersShocking: One AI startup's revenue could surge 4,735%Manward PressThe Department of Defense Has a New Drone ContractorThe Tomorrow Investor[URGENT] DO NOT Touch These AI Stocks!Weiss RatingsAI “wealth window” is closing June 25thParadigm PressStock-Picking AI Predicts #1 Stock of 2024AltimetryElon Musk Secret Crypto Plot ExposedCrypto 101 MediaThe #1 lithium battery stock to have on your radar in 2024!Smallcaps DailyThe AI Stock that’s Disrupting Every IndustryStockEarnings Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding IsoPlexis Co. Please log in to your account or sign up in order to add this asset to your watchlist. Get 30 Days of MarketBeat All Access Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools: Best-in-Class Portfolio Monitoring View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio. Stock Ideas and Recommendations Get daily stock ideas from top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report. Advanced Stock Screeners and Research Tools Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis. Start Your 30-Day Free Trial Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
